NCI Center for Cancer Research’s Post

📣 CANCER CURRENTS: In this Q&A, Stephanie Goff, M.D., Senior Research Physician in our Surgery Branch, talks about what’s known about CAR T-cell therapy and second cancers and what this issue means in general for patients and this area of research. Dr. Goff specializes in developing and testing gene-engineered T-cell therapies, including CARs. ➡ Read more: https://lnkd.in/dtaJXik6 National Cancer Institute (NCI), National Institutes of Health (NIH): Intramural Research Program (IRP) #CancerResearch #Immunotherapy #Innovation #Technology #Medicine

  • Dr. Goff headshot attached to Quote card.
  • CAR T-cell therapies are genetically engineered T cells that can attack cancer cells. FDA is investigating instances of secondary T-cell cancers in people treated with CAR T-cell therapies.

Credit: iStock/selvanegra

We would like to inform you that your post has been successfully published on OncoDaily. Thank you for sharing such valuable content. https://oncodaily.com/blog/125848

Like
Reply
Dr. Reza Rahavi

Experimental Medicine , Faculty of Medicine, UBC, Vancouver | Medical Content Writing

2w

What are some promising advancements in cancer treatment that you believe will shape the future of oncology? #MedicalInnovations https://lnkd.in/guWiXGVC

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics